Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2025-12-27 @ 11:44 PM
Study NCT ID:
NCT06231693
Status:
TERMINATED
Last Update Posted:
2025-05-08
First Post:
2024-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-04
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-03-26
Completion Date Type:
ACTUAL
First Submit Date:
2024-01-11
First Submit QC Date:
None
Study First Post Date:
2024-01-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-06
Last Update Post Date:
2025-05-08
Last Update Post Date Type:
ACTUAL